 Tejas Patil
Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 31 | 2025 | 1045 | 5.400 |
Why?
| | Lung Neoplasms | 33 | 2025 | 2327 | 3.970 |
Why?
| | Aniline Compounds | 7 | 2025 | 96 | 1.830 |
Why?
| | Acrylamides | 6 | 2025 | 58 | 1.820 |
Why?
| | Mutation | 17 | 2025 | 3682 | 1.610 |
Why?
| | ErbB Receptors | 15 | 2025 | 601 | 1.410 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1558 | 1.180 |
Why?
| | Protein-Tyrosine Kinases | 7 | 2023 | 430 | 0.980 |
Why?
| | Proto-Oncogene Proteins | 7 | 2023 | 632 | 0.970 |
Why?
| | Pemetrexed | 1 | 2024 | 32 | 0.930 |
Why?
| | Brain Neoplasms | 6 | 2024 | 1163 | 0.830 |
Why?
| | Protein Kinase Inhibitors | 10 | 2025 | 875 | 0.790 |
Why?
| | Pleural Neoplasms | 2 | 2024 | 23 | 0.730 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2021 | 744 | 0.650 |
Why?
| | Pyrimidines | 7 | 2025 | 446 | 0.650 |
Why?
| | Receptor, ErbB-2 | 2 | 2019 | 325 | 0.590 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 10 | 0.520 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 87 | 0.480 |
Why?
| | Adenocarcinoma | 2 | 2018 | 888 | 0.460 |
Why?
| | Mesothelioma | 2 | 2024 | 38 | 0.430 |
Why?
| | Retrospective Studies | 18 | 2025 | 14404 | 0.390 |
Why?
| | Indoles | 5 | 2025 | 371 | 0.370 |
Why?
| | Aged, 80 and over | 7 | 2025 | 7029 | 0.370 |
Why?
| | Neoplasm Staging | 6 | 2024 | 1288 | 0.360 |
Why?
| | Middle Aged | 21 | 2025 | 30812 | 0.350 |
Why?
| | Gene Rearrangement | 4 | 2022 | 146 | 0.350 |
Why?
| | Antineoplastic Agents | 5 | 2024 | 2041 | 0.330 |
Why?
| | Aged | 16 | 2025 | 21892 | 0.330 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 258 | 0.320 |
Why?
| | Lung | 2 | 2018 | 3745 | 0.310 |
Why?
| | Humans | 38 | 2025 | 128019 | 0.300 |
Why?
| | Pyrazoles | 2 | 2021 | 401 | 0.270 |
Why?
| | Survival Rate | 6 | 2020 | 1870 | 0.260 |
Why?
| | Neoplasm Metastasis | 3 | 2024 | 608 | 0.260 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2020 | 620 | 0.250 |
Why?
| | Disease Progression | 3 | 2024 | 2598 | 0.250 |
Why?
| | Female | 23 | 2025 | 68016 | 0.250 |
Why?
| | Medical Oncology | 2 | 2025 | 271 | 0.250 |
Why?
| | Biomarkers, Tumor | 3 | 2024 | 1175 | 0.240 |
Why?
| | Central Nervous System | 3 | 2023 | 254 | 0.240 |
Why?
| | Thoracic Neoplasms | 1 | 2025 | 35 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-met | 2 | 2023 | 74 | 0.230 |
Why?
| | Neoadjuvant Therapy | 2 | 2024 | 381 | 0.230 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 384 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2021 | 29 | 0.220 |
Why?
| | Male | 20 | 2025 | 62757 | 0.220 |
Why?
| | Oncogenes | 3 | 2022 | 109 | 0.220 |
Why?
| | Research Personnel | 1 | 2025 | 156 | 0.210 |
Why?
| | Oncogene Addiction | 1 | 2023 | 5 | 0.210 |
Why?
| | Radiosurgery | 2 | 2024 | 318 | 0.210 |
Why?
| | Adult | 10 | 2025 | 35176 | 0.200 |
Why?
| | Chemoradiotherapy | 1 | 2024 | 209 | 0.200 |
Why?
| | Clinical Trials as Topic | 2 | 2025 | 997 | 0.200 |
Why?
| | Acetonitriles | 1 | 2021 | 10 | 0.190 |
Why?
| | Pyridines | 2 | 2021 | 474 | 0.180 |
Why?
| | Circulating Tumor DNA | 1 | 2020 | 28 | 0.170 |
Why?
| | Lactams | 1 | 2019 | 21 | 0.170 |
Why?
| | Lactams, Macrocyclic | 1 | 2019 | 49 | 0.160 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 10 | 0.160 |
Why?
| | Gene Amplification | 1 | 2019 | 103 | 0.160 |
Why?
| | Aminopyridines | 1 | 2019 | 95 | 0.160 |
Why?
| | Genes, erbB-1 | 1 | 2018 | 17 | 0.160 |
Why?
| | Piperazines | 1 | 2021 | 332 | 0.150 |
Why?
| | Oncogene Proteins | 1 | 2018 | 52 | 0.150 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2018 | 84 | 0.150 |
Why?
| | Thromboembolism | 1 | 2018 | 101 | 0.140 |
Why?
| | Disease-Free Survival | 2 | 2017 | 647 | 0.140 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 115 | 0.140 |
Why?
| | Biomarkers, Pharmacological | 1 | 2017 | 26 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 262 | 0.140 |
Why?
| | Smad4 Protein | 1 | 2017 | 38 | 0.140 |
Why?
| | Prognosis | 3 | 2020 | 3766 | 0.140 |
Why?
| | Gene Deletion | 1 | 2018 | 369 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2024 | 1354 | 0.140 |
Why?
| | Erlotinib Hydrochloride | 1 | 2017 | 69 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 189 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 175 | 0.130 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4853 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2023 | 955 | 0.130 |
Why?
| | Colorectal Neoplasms | 1 | 2021 | 746 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2018 | 633 | 0.110 |
Why?
| | Tomography, X-Ray Computed | 2 | 2022 | 2509 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2614 | 0.090 |
Why?
| | Smoking | 1 | 2018 | 1459 | 0.090 |
Why?
| | Quality of Life | 1 | 2022 | 2672 | 0.090 |
Why?
| | Survival Analysis | 2 | 2025 | 1262 | 0.080 |
Why?
| | Biomarkers | 1 | 2017 | 3874 | 0.060 |
Why?
| | Pleura | 1 | 2024 | 22 | 0.060 |
Why?
| | Consolidation Chemotherapy | 1 | 2024 | 9 | 0.060 |
Why?
| | Carbazoles | 1 | 2024 | 84 | 0.060 |
Why?
| | Canada | 1 | 2025 | 344 | 0.050 |
Why?
| | Peritoneum | 1 | 2023 | 41 | 0.050 |
Why?
| | Kelch-Like ECH-Associated Protein 1 | 1 | 2023 | 10 | 0.050 |
Why?
| | Platinum | 1 | 2023 | 44 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2023 | 178 | 0.050 |
Why?
| | Taxoids | 1 | 2023 | 95 | 0.050 |
Why?
| | Piperidines | 1 | 2024 | 190 | 0.050 |
Why?
| | Response Evaluation Criteria in Solid Tumors | 1 | 2022 | 17 | 0.050 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2023 | 67 | 0.050 |
Why?
| | Exons | 1 | 2023 | 338 | 0.050 |
Why?
| | Young Adult | 1 | 2018 | 12281 | 0.050 |
Why?
| | Appendiceal Neoplasms | 1 | 2021 | 26 | 0.050 |
Why?
| | Meningeal Neoplasms | 1 | 2021 | 93 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2022 | 221 | 0.040 |
Why?
| | Gene Fusion | 1 | 2018 | 24 | 0.040 |
Why?
| | Protein Conformation | 1 | 2021 | 853 | 0.040 |
Why?
| | Topoisomerase I Inhibitors | 1 | 2017 | 16 | 0.040 |
Why?
| | Electronic Health Records | 1 | 2024 | 973 | 0.030 |
Why?
| | Registries | 1 | 2024 | 1873 | 0.030 |
Why?
| | Etoposide | 1 | 2017 | 148 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 226 | 0.030 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 212 | 0.030 |
Why?
| | Cranial Irradiation | 1 | 2017 | 68 | 0.030 |
Why?
| | Immunotherapy | 1 | 2020 | 586 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 851 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2017 | 163 | 0.030 |
Why?
| | Salvage Therapy | 1 | 2017 | 133 | 0.030 |
Why?
| | Genomics | 1 | 2020 | 714 | 0.030 |
Why?
| | DNA Repair | 1 | 2017 | 205 | 0.030 |
Why?
| | United States | 2 | 2025 | 13785 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1492 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 630 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 443 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5378 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1199 | 0.030 |
Why?
| | Databases, Factual | 1 | 2019 | 1264 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 754 | 0.030 |
Why?
| | Mass Screening | 1 | 2020 | 1145 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1343 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3371 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2018 | 3009 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2261 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 6355 | 0.020 |
Why?
| | Time Factors | 1 | 2020 | 6479 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 10110 | 0.020 |
Why?
| | Signal Transduction | 1 | 2017 | 4812 | 0.010 |
Why?
|
|
Patil's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|